There is an ongoing phase III trial (NCT06346392), known as the CLARITY-Gastric01 trial, which will evaluate the use of AZD0901 monotherapy vs. investigator-choice chemotherapy for patients with previously treated CLDN18.2-positive metastatic GC/GEJC [66]. Here, CLDN18 is linked to gastric cancer.